Author:
Friedman Mark T.,West Kamille A.,Bizargity Peyman,Annen Kyle,Gur H. Deniz,Hilbert Timothy
Publisher
Springer International Publishing
Reference9 articles.
1. CABLIVI® prescribing information. Ghent: Ablynx N.V. September 2020.
2. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169–81.
3. SOLIRIS® prescribing information. Boston, MA: Alexion Pharmaceuticals. November 2020.
4. ULTOMIRIS® prescribing information. Boston, MA: Alexion Pharmaceuticals. October 2020.
5. Jeantet G, Pernin V, Brunot V, Roccabianca A, Macombe A, Szwarc I, et al. Successful treatment of a Streptococcus pneumoniae-associated haemolytic uraemic syndrome by eculizumab. Clin Kid J. 2019;12(1):106–9.